2012, PLoS One) Enhancement of long-term potentiation, a synaptic plasticity marker Effects on dendritic spine density in hippocampal neurons Activation of HGF/c-Met signaling in cultured neurons (McCoy et al
The maximum dose of semaglutide for obesity is 2.4 mg weekly in the current guidelines
A compendium of ruminant gastrointestinal phage genomes revealed a higher proportion of lytic phages than in any other environments
Disclosures: Alejandra Paredes-Marin: Nothing to Disclose, Julia Napoli: Nothing to Disclose, Vikram Sivakumar: Nothing to Disclose, Christian Near: Nothing to Disclose, Dakota Trick: Nothing to Disclose, Helen Adams: Nothing to Disclose, Alyson Harty: Nothing to Disclose, Ritu Agarwal: Nothing to Disclose, Douglas Dieterich: Gilead: Consultant, madrigal: Speaking and Teaching, John Bucuvalas: Mirum Pharmaceutical: consultant, Madrigal Pharmaceutical: Consultant, Neurogene: Consultant, Iecure: Consultant, Tatyana Kushner: Gilead: Grant/Research Support, Gilead: Advisor, GSK: Advisor, Eiger: Advisor, Jaime Chu: Albireo: Consultant, Swati Antala: Nothing to Disclose, Asher Leviton: Nothing to Disclose, Augusto Villanueva: Nothing to Disclose, Scott Friedman: 89 Bio: Consultant, Boehringer Ingelheim: Consultant, Boston Pharmaceutical: Consultant, Bristol Myers Squibb: Consultant, Merck: Consultant, Glycotest: Consultant, Morphic Therapeutics: Consultant, HepGene: Consultant, North Sea Therapeutics: Consultant, Pfizer Pharmaceuticals: Consultant, Sagimet: Consultant, Scholar Rock: Consultant, Prosciento: Consultant, Seal Rock: Consultant, Surrozen: Consultant, Takeda Pharmaceuticals: Consultant, Rachel Smith: Nothing to Disclose, Xiaotao Zhang: Nothing to Disclose, Meena Bansal: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose 1189 CLINICAL, PSYCHOSOCIAL AND SOCIAL DETERMINANTS OF HEALTH FACTORS ASSOCIATED WITH DEGREE OF HEPATIC STEATOSIS AND LIVER STIFFNESS AMONG OVERWEIGHT AND OBESE ADULTS AT RISK OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Monica Tincopa 1 Lisa Richards 1 Rohit Loomba 1 , 1 University of California, San Diego Background: The severity of metabolic dysfunction-associated steatotic liver disease (MASLD) among patients with overweight and obesity is heterogeneous and may be moderated by behavioral, psychosocial and social determinant of health (SDOH) factors
1993;49:151154.[PubMed] [Google Scholar][149] Rehak J, Vymazal M
Retrieved 24 February 2020
